BiotechTube

Upadacitinib + Upadacitinib Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata

Trial Timeline

Jun 19, 2025 → Feb 1, 2029

NCT ID
NCT07023302

About Upadacitinib + Upadacitinib Placebo

Upadacitinib + Upadacitinib Placebo is a phase 3 stage product being developed by AbbVie for Alopecia Areata. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07023302. Target conditions include Alopecia Areata.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07023302Phase 3Recruiting

Competing Products

20 competing products in Alopecia Areata

See all competitors
ProductCompanyStageHype Score
BaricitinibEli LillyPhase 2
52
CTP-543Sun PharmaceuticalPhase 2/3
65
CTP-543Sun PharmaceuticalPhase 3
77
Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2/3
65
Baricitinib 4 MG Oral TabletEli LillyApproved
85
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
minoxidilJohnson & JohnsonPhase 3
77
5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3
77
Minoxidil + vehicle of 5% Minoxidil topical foamJohnson & JohnsonPhase 2
52
5% Minoxidil Topical Foam + Vehicle Topical FoamJohnson & JohnsonPhase 3
77
Upadacitinib + PlaceboAbbViePhase 3
77
Secukinumab + PlaceboNovartisPhase 2
52
DaxdilimabAmgenPhase 2
51
RitlecitinibPfizerPre-clinical
22
LITFULOPfizerPre-clinical
22
RitlecitinibPfizerPre-clinical
22
Ritlecitinib higher dose + Ritlecitinib lower dose + PlaceboPfizerPhase 3
76
RitlecitinibPfizerPre-clinical
22

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85